BRIEF—Nouscom appoints CEO and CMO

Swiss immuno-oncology company Nouscom has appointed Marina Udier as chief executive officer and Patricia Delaite as chief medical officer, with immediate effect.

Nouscom is developing off-the-shelf and personalized cancer neoantigen vaccines, and is working on lead candidate NOUS-209. Clinical studies are expected to start later this year.

Dr Udier joined Nouscom as chief operating officer in 2016 from Versant Ventures and was appointed interim CEO in May 2019.

Dr Delaite was formerly chief medical officer at AMAL Therapeutics, designing and implementing a first-in-human therapeutic cancer vaccine trial.